Anti-tumor drug

BeiGene was slapped with a patent lawsuit by U.S. rival AbbVie in June, and suffered another blow to its global ambitions in July when Novartis pulled out of a drug collaboration.

Sales success comes with side effects for drug maker BeiGene

The Chinese biotech’s product revenues surged nearly 82% in the second quarter, driven by forecast-beating sales of its core cancer drugs Key Takeaways: Global sales of BeiGene's anti-tumor drug zanubrutinib…
BGNE.US 6160.HK

Recent Articles

RELATED ARTICLES

  1. The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising.
    BeiGene still bleeding red ink despite blockbuster drug
    BGNE.US 6160.HK 688235.SHG
  2. AstraZeneca pays hefty price for Chinese weight-loss drug
    AZN.US
  3. Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
    1877.HK 688180.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva